Scott D. Collins

1.9k total citations
10 papers, 151 citations indexed

About

Scott D. Collins is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Organic Chemistry. According to data from OpenAlex, Scott D. Collins has authored 10 papers receiving a total of 151 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 5 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Organic Chemistry. Recurrent topics in Scott D. Collins's work include HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Scott D. Collins is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Scott D. Collins collaborates with scholars based in United States and China. Scott D. Collins's co-authors include E. A. Serafetinides, Mervin L. Clark, Carl Uli Bialucha, Lisa D. Eli, Seth A. Ettenberg, Richard Kurupi, Joan T. Garrett, Carlos L. Arteaga, Cammie R. Sutton and Qing Sheng and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Lab on a Chip.

In The Last Decade

Scott D. Collins

9 papers receiving 147 citations

Peers

Countries citing papers authored by Scott D. Collins

Since Specialization

Citations

This map shows the geographic impact of Scott D. Collins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott D. Collins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott D. Collins more than expected).

Fields of papers citing papers by Scott D. Collins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott D. Collins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott D. Collins. The network helps show where Scott D. Collins may publish in the future.

Co-authorship network of co-authors of Scott D. Collins

This figure shows the co-authorship network connecting the top 25 collaborators of Scott D. Collins. A scholar is included among the top collaborators of Scott D. Collins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott D. Collins. Scott D. Collins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	High speed microturbine mixer for kinetically controlled synthesis 2025 ·Lab on a Chip ·(unknown), Scott D. Collins, (unknown), Michael D. Mason, R. L. Smith	1
2	Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates 2024 ·Molecular Cancer Therapeutics ·Joshua D. Thomas, (unknown), Mao Yin, Natalya D. Bodyak, (unknown), Marina Protopopova, (unknown), Brian Jones, Liping Yang, Daniel Custar, (unknown), Damon R. Demady, Scott D. Collins, Ling Xu, (unknown), LiuLiang Qin, Elena Ter‐Ovanesyan, Marc Damelin, Dorin Toader, Timothy B. Lowinger	0
3	Abstract 5810: The impact of scaffold, linker, homogeneity and payload selection on the efficacy and tolerability of anti-tubulin ADCs 2024 ·Cancer Research ·Scott D. Collins, Natalie Keirstead, Marc Damelin, Dorin Toader, (unknown), Niyanta Kumar, (unknown), (unknown), (unknown), Mohan Bala, Timothy B. Lowinger	1
4	Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates 2023 ·Journal of Medicinal Chemistry ·Jeremy R. Duvall, Joshua D. Thomas, Raghida A. Bukhalid, (unknown), K. W. Bentley, Scott D. Collins, Timothy K. Eitas, Brian Jones, (unknown), (unknown), Marina Protopopova, Soumya S. Ray, Elena Ter‐Ovanesyan, Ling Xu, Liping Yang, (unknown), Marc Damelin, Dorin Toader, Timothy B. Lowinger	32
5	Abstract 1756: Antitumor effect of XMT1660, a B7H4 targeting antibody drug conjugate, in an unselected panel of patient derived xenograft models of breast cancer 2022 ·Cancer Research ·Scott D. Collins, (unknown), Shawn P. Fessler, Jason Wang, Rebecca Mosher	1
6	Abstract 2687: Dolasynthen–a novel, homogeneous Auristatin F hydroxypropyl amide antibody-drug conjugate platform 2019 ·Cancer Research ·Dorin Toader, Marc Damelin, Anouk Dirksen, (unknown), Scott D. Collins, Barrett J. Nehilla, Jian Xu, Ling Xu, (unknown), (unknown), Winnie Lee, Susan M. Clardy, (unknown), LiuLiang Qin, Patrick R. Conlon, (unknown), Chen‐Ni Chin, David H. Lee, Timothy B. Lowinger	1
7	Tongxinluo Improves Apolipoprotein E-Deficient Mouse Heart Function 2018 ·Chinese Medical Journal ·(unknown), Song Gao, Yong‐Jian Geng, (unknown), (unknown), Harnath Shelat, Scott D. Collins, (unknown), Yi‐Ling Wu	10
8	Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates 2017 ·Molecular & Cellular Oncology ·Scott D. Collins, Carl Uli Bialucha, Juliet Williams, Hui Gao	1
9	Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers 2013 ·Cancer Research ·Joan T. Garrett, Cammie R. Sutton, Richard Kurupi, Carl Uli Bialucha, Seth A. Ettenberg, Scott D. Collins, Qing Sheng, (unknown), Lisa D. Eli, Carlos L. Arteaga	72
10	HALOPERIDOL, CLOPENTHIXOL, AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA 1972 ·The Journal of Nervous and Mental Disease ·E. A. Serafetinides, Scott D. Collins, Mervin L. Clark	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact